The facility produces Potassium Clavulanate which is used to treat conditions such as pneumonia, bronchitis and infections of the skin. The expansion will help meet growing demand from developing countries. GSK is receiving a £1.5m Scottish Enterprise Regional Selective Assistance grant towards the cost.
